|
Zimulti Treatment
Zimulti (Rimonabant) being an anorectic anti - obesity drug, is one of highly awaited pill for weight loss. Developed by Sanofi - Aventis, and launched in Britain. The multi - functional pill is prescribed for a period of two years. Along with weight reduction it fights nicotine addiction. Roll outs are soon expected in Germany, Ireland, Denmark, Finland and Norway. Generating an interest among obese people.it is expected to be available by the end of June 2006 in the UK. Acomplia has regenerated a huge response and has thus captured the market. It has been stated that if the drug is approved in the United States, it will be sold under the trade name Zimulti.
Patient information:
Acomplia is a CB1 cannabinoid receptor antagonist which has been approved for use anywhere in the world. Acomplia works by affecting the Endocannabinoid system which controls appetite and energy expenditure. It is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients with BMI greater than 27kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia. Creating balance it blocks the receptors thus suppressing the appetite and the urge to overeat. Though used mainly for obese people, it also helps in smoking cessation. Its USP lies in its dual nature for smoking as well as obesity. Though has certain side effects, the minor effects gradually diminish.
Acomplia is found to be effective in helping smokers quit smoking. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS has been designed to explore two smoking related therapies which are:
- To help prevent weight gain in former smokers.
- Use rimonabant directly to aid in smoking cessation.
The results have shown that Acomplia diet pills is effective for both uses.
Buy Xenical USA, Canada/ Buy Xenical UK Rest world
Buy Reductil UK Rest world
Buy Alli Diet Pill
Buy Hoodia Diet Pills
|
Acomplia
Menu 
